Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285227 | 0.88 | TSHR (0.49) | TSHRHCAR2CYP3A4TDP1ATM | |
| SCHEMBL11451456 | 0.82 | TSHR (0.45) | TSHRCYP3A4TDP1ATMCA2 | |
| Ethyl Fumarate SCHEMBL6133836 | 0.82 | HCAR2 (0.48) | TSHRHCAR2CYP3A4TDP1ACHE | |
| SCHEMBL11008253 | 0.82 | TSHR (0.42) | TSHRCYP3A4TDP1ATMCA2 | |
| Acrylic Acid SCHEMBL28097267 | 0.81 | TSHR (0.49) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL3102870 | 0.81 | TSHR (0.46) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL7636498 | 0.81 | TSHR (0.40) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL28119989 | 0.81 | TSHR (0.42) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL6290785 | 0.80 | TSHR (0.45) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL20578185 | 0.80 | TSHR (0.45) | TSHRCYP3A4TDP1ATMCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680088-B1 | Taste-masked formulation comprising clarithromycin | SANDOZ AG (CH) | 2008-12-03 | — | — | EP | claimed |
| EP-2819658-A2 | PHARMACEUTICAL FORMULATION CONTAINING FLUPIRTINE | MEDA Pharma GmbH & Co. KG (DE) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013127539-A2 | PHARMACEUTICAL FORMULATIONS | MEDA PHARMA GMBH & CO. KG (DE) | 2013-09-06 | — | — | WO | disclosed |
| WO-2007063095-A1 | USE OF ZINC SALTS OF LIPOIC ACID FOR TREATING FAT METABOLISM DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006042728-A2 | USE OF STABLE AMMONIUM LIPONATE SALTS FOR THE TREATMENT OF DIABETIC AND OTHER DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-27 | — | — | WO | disclosed |
| EP-1622891-A1 | STABLE AMMONIUM SALTS OF ALPHA-LIPONIC ACID, THE PRODUCTION THERE OF AND THE USE OF THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004092157-A1 | STABLE AMMONIUM SALTS OF α-LIPONIC ACID, THE PRODUCTION THEREOF AND THE USE OF THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2004-10-28 | — | — | WO | disclosed |
| EP-0654484-B1 | Pharmaceutical compositions containing inclusion compounds of thioctic or dihydroliponic acid with cyclodextrins and in granule form or in chewable or effervescent tablet form | VIATRIS GMBH (DE) | 2003-04-23 | — | — | EP | disclosed |
| EP-0615754-B1 | Solid controlled-release administration forms containing flupertine | AWD PHARMA GMBH & CO KG (DE) | 2002-07-10 | — | — | EP | disclosed |
| EP-0659410-B1 | Use of the compound flupirtin for the preparation of a medicament against muscle bracing | ASTA MEDICA AG (DE) | 2001-10-17 | — | — | EP | disclosed |
| WO-1994027592-A1 | USE OF DIHYDROLIPONIC ACID AS AN OPHTHALMOLOGIC AGENT AND FOR THE SUPPRESSION OF INCOMPATABILITY REACTIONS AT THE INTERFACES BETWEEN IMPLANTS AND LIVING BODY TISSUE | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1994-12-08 | — | — | WO | disclosed |
| EP-0378086-B1 | Use of the agent azelastine in the treatment of psoriasis | ASTA MEDICA AG (DE) | 1994-10-26 | — | — | EP | disclosed |
| EP-0615754-A1 | Solid controlled-release administration forms containing flupertine | ASTA Medica Aktiengesellschaft (DE) | 1994-09-21 | — | — | EP | disclosed |
| EP-0572922-A1 | Synergistic combinations comprising lipoic acid and vitamines in medicaments | ASTA Medica Aktiengesellschaft (DE) | 1993-12-08 | — | — | EP | disclosed |
| EP-0338444-B1 | Substituted release azelastine containing medicaments | ASTA MEDICA AG (DE) | 1993-11-24 | — | — | EP | disclosed |
| EP-0277352-B1 | SYNERGISTIC MIXTURE OF AZELASTINE AND THEOPHYLLINE OR OF AZELASTINE AND BETA-MIMETICS | ASTA Pharma Aktiengesellschaft (DE) | 1991-10-16 | — | — | EP | disclosed |
| EP-0427247-A2 | Pharmaceutical composition with R-alpha-lipoic acid or S-alpha-lipoic acid as the active ingredient | ASTA Medica Aktiengesellschaft (DE) | 1991-05-15 | — | — | EP | disclosed |
| EP-0427246-A2 | Pharmaceutical compositions comprising sulfur containing carboxylic acids as the active agent as well as their use for combatting retroviruses | ASTA Medica Aktiengesellschaft (DE) | 1991-05-15 | — | — | EP | disclosed |
| EP-0382066-A2 | Use of dihydroliponic acid as an analgetic, antiphlogistic and/or cytoprotective agent | ASTA Medica Aktiengesellschaft (DE) | 1990-08-16 | — | — | EP | disclosed |
| EP-0338444-A1 | Substituted release azelastine containing medicaments | ASTA Medica Aktiengesellschaft (DE) | 1989-10-25 | — | — | EP | disclosed |